Summary:
Phase 2, double-blind, placebo-controlled study, evaluating the Efficacy and Safety of GATE-251 versus placebo for the reduction of symptoms of Major Depressive Disorder (MDD).
Qualified Participants Must:
• Be 18 to 64 years of age
•
Diagnosed with Major Depressive Disorder (MDD)
•
Have anxiety
•
Have Insomnia